Skip to main content
Premium Trial:

Request an Annual Quote

FDA Extends Comment Phase for Companion IVD Guidance

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has extended by a month the period during which it will accept public comments on its recent draft guidance outlining its planned policy for accepting and reviewing applications for companion diagnostic devices.

FDA said in a Federal Register posting Friday that it will accept public responses to the "In Vitro Companion Diagnostic Devices" draft guidance for industry and FDA staff, which it released in mid-July, through Oct. 12.

The guidance is aimed at drug developers who are developing a therapeutic that depends on the use of and IVD companion test, and for those developing companion tests that are intended to be used with a corresponding therapeutic product.

FDA said in the guidance that it expects that these companies will file applications on the drug and the test concurrently.

"The rationale of the guidance was to let people know before we approved these kinds of drugs – where you actually have to select the population with a test – that we need to know that the test actually works," Elizabeth Mansfield, FDA Director of Personalized Medicine Staff in the Center for Devices and Radiological Health, told GenomeWeb Daily News when the guidance was released. "The way we've been handling it so far is that we're using the two different regulatory mechanisms as they already exist."

She added, "We don't require the device company to do a whole separate trial. We're using the same regulatory pathways as ever, we're just able to tell the different companies what parts of it they need to fulfill, and what parts, if any" they don't.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.